Deltex Medical (LON:DEMG) expects details for the first phase of the NHS’s planned national roll-out of fluid management monitoring to be published by Christmas.
Ewan Phillips, chief executive, said it had been informed by Department of Health this will include targets and financial incentives.
One of the NHS‘s key initiatives is to install oesophageal Doppler monitoring (ODM) or similar fluid management monitoring technologies across the health service.
Once this goes ahead it should be a major boost to Deltex Medical’s CardioQ-ODM, which the company says is already market leader in the south of England where the roll-out is expected to start.
Deltex said today a study in Sweden had further demonstrated the advantage of ODM over a rival technology developed by Lidco (LON:LID).
The Karolinska Institute in Sweden found the uncalibrated Pulse Pressure Waveform Analysis (PPWA) system used in the study to be unable to replicate accurately measurements from the CardioQ-ODM during major surgery.
Phillips added; “This independent study from one of Europe's leading teaching hospitals is very timely. It addresses any misconception that the device used in this study could be considered similar to ODM in the demanding environment of major surgery.”
"ODM is the only fluid management monitoring technology proven to deliver the improved outcomes sought across the NHS and only CardioQ-ODM has been evaluated and recommended by the National Institute of Health and Clinical Excellence (NICE) for use by clinicians for intra operative fluid management," Phillips added.